Literature DB >> 20558977

Tumor risk in disorders of sex development.

J Pleskacova1, R Hersmus, J W Oosterhuis, B A Setyawati, S M Faradz, M Cools, K P Wolffenbuttel, J Lebl, S L Drop, L H Looijenga.   

Abstract

Certain patients with disorders of sex development (DSD), who bear Y chromosome material in their karyotype, are at increased risk for the development of type II germ cell tumors (GCT), which arise from early fetal germ cells. DSD gonads frequently harbor immature germ cells which express early fetal germ cell markers. Some of them (e.g. OCT3/4 and NANOG) seem to be of pathogenetic relevance in GCT development providing cells with the ability of pluripotency, proliferation and apoptosis suppression. Also TSPY (testis-specific protein Y-encoded), the main candidate for the so-called gonadoblastoma locus on Y chromosome, is overexpressed in germ cells of DSD patients and possibly contributes to their survival and proliferation. Nowadays, the use of immunohistochemical methods is highly relevant in identifying DSD gonads at risk. The risk for GCT development varies. While the prevalence of GCT is 15% in patients with partial androgen insensitivity, it may reach more than 30% in patients with gonadal dysgenesis. Patients with complete androgen insensitivity and ovotesticular DSD develop malignancies in 0.8% and 2.6% of cases, respectively. However, these data may be biased for various reasons. To better estimate the risk in individual groups of DSD, further investigations on large patient series are needed.

Entities:  

Mesh:

Year:  2010        PMID: 20558977     DOI: 10.1159/000314536

Source DB:  PubMed          Journal:  Sex Dev        ISSN: 1661-5425            Impact factor:   1.824


  34 in total

1.  Maintenance of Drosophila germline stem cell sexual identity in oogenesis and tumorigenesis.

Authors:  Laura Shapiro-Kulnane; Anne Elizabeth Smolko; Helen Karen Salz
Journal:  Development       Date:  2015-03-15       Impact factor: 6.868

2.  Ovarian yolk sac tumor in a patient with sexual differentiation disorder: a case description.

Authors:  Chao Lian Xie; Chun Rong Peng; Jia Xin Yan; Lin Xia Wang; Peng Zhou
Journal:  Quant Imaging Med Surg       Date:  2021-07

3.  Frequency and distribution of primary site among gender minority cancer patients: An analysis of U.S. national surveillance data.

Authors:  Rebecca Nash; Kevin C Ward; Ahmedin Jemal; David E Sandberg; Vin Tangpricha; Michael Goodman
Journal:  Cancer Epidemiol       Date:  2018-03-09       Impact factor: 2.984

Review 4.  Genetics of testicular germ cell tumors.

Authors:  Nirmish Singla; John T Lafin; Rashed A Ghandour; Samuel Kaffenberger; James F Amatruda; Aditya Bagrodia
Journal:  Curr Opin Urol       Date:  2019-07       Impact factor: 2.309

Review 5.  Testicular cancer: biology and biomarkers.

Authors:  Leendert H J Looijenga; Hans Stoop; Katharina Biermann
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

6.  The "Normalization" of Intersex Bodies and "Othering" of Intersex Identities in Australia.

Authors:  Morgan Carpenter
Journal:  J Bioeth Inq       Date:  2018-05-07       Impact factor: 1.352

Review 7.  A practical guide for evaluating gonadal germ cell tumor predisposition in differences of sex development.

Authors:  Louise C Pyle; Katherine L Nathanson
Journal:  Am J Med Genet C Semin Med Genet       Date:  2017-05-25       Impact factor: 3.908

8.  Sex, stem cells and tumors in the Drosophila ovary.

Authors:  Helen K Salz
Journal:  Fly (Austin)       Date:  2012-12-03       Impact factor: 2.160

9.  Expression pattern of clinically relevant markers in paediatric germ cell- and sex-cord stromal tumours is similar to adult testicular tumours.

Authors:  Christiane Hammershaimb Mosbech; Terje Svingen; John Erik Nielsen; Birgitte Groenkaer Toft; Catherine Rechnitzer; Bodil Laub Petersen; Ewa Rajpert-De Meyts; Christina Engel Hoei-Hansen
Journal:  Virchows Arch       Date:  2014-07-30       Impact factor: 4.064

Review 10.  Environmental influences on ovarian dysgenesis - developmental windows sensitive to chemical exposures.

Authors:  Hanna Katarina Lilith Johansson; Terje Svingen; Paul A Fowler; Anne Marie Vinggaard; Julie Boberg
Journal:  Nat Rev Endocrinol       Date:  2017-04-28       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.